Member Info for one4one

However, beyond the clinical protocol itself lies an equally important dimension: manufacturing. CAR-T therapy production is traditionally time-intensive, involving the extraction, genetic modification, expansion, and reinfusion of a patient’s own T cells. This autologous process can take several weeks, a timeline that is particularly challenging for aggressive diseases like AML.

Hemogenyx’s transition toward integrating AI-assisted and robotic manufacturing systems represents a strategic attempt to compress this timeline. Automation can streamline several bottlenecks: cell isolation, viral transduction, and expansion phases can be standardized and monitored in real time using machine learning algorithms. Robotics can reduce human handling errors and variability, ensuring more consistent product quality across batches. In theory, such a system could reduce vein-to-vein time (from cell collection to reinfusion) from several weeks to potentially under ten days, though this remains dependent on validation and regulatory acceptance.🐭

In the near-term timeframe—spanning the next 6 to 18 months—the company’s progress will likely hinge on three parallel tracks. First, successful escalation to full-dose adult cohorts without severe adverse events will be necessary to justify continued expansion. Second, the initiation and early readouts from the paediatric arm will provide important differentiation, as paediatric AML remains an area of significant unmet need. Third, and perhaps most strategically, will be the demonstration that AI-augmented manufacturing can operate reliably under clinical-grade conditions.🐭

If these elements align, Hemogenyx could move from a proof-of-concept stage toward a more scalable therapeutic platform. However, challenges remain substantial. Regulatory bodies will scrutinize not only clinical outcomes but also the reproducibility and safety of automated manufacturing systems. Moreover, integrating AI into such a tightly regulated biomedical process introduces questions around validation, auditability, and control.

In summary, Hemogenyx is not merely advancing a clinical trial; it is attempting to modernize the infrastructure behind CAR-T therapy itself. The coming phase will test whether innovations in dosing strategy, patient inclusion, and AI-driven production can converge into a viable, scalable treatment pathway for AML.

The introduction of AI requires the Guidance of a Human Shepperd !

In the near-term timeframe—spanning the next 6 to 18 months—the company’s progress will likely hinge on three parallel tracks. First, successful escalation to full-dose adult cohorts without severe adverse events will be necessary to justify continued expansion. Second, the initiation and early readouts from the paediatric arm will provide important differentiation, as paediatric AML remains an area of significant unmet need. Third, and perhaps most strategically, will be the demonstration that AI-augmented manufacturing can operate reliably under clinical-grade conditions🐭

Alde your post is a Red rag to the bulls "repercussion's they will trash the Avacta thread as they did with myself "childish behaviour" led me to not post on the forum of my other investment🐭

Neurotoxicity, "ICANS" the younger generation have a stronger immune defence system but a more active brain and prone to "neurotoxicity the nippers before the enrolment of the c/t will undertake cogitation tests & will be monitored during the c/trial 🐭

I have collated a R & D about HG-CT-1 clinical trial "with reference to timelines below is a guide used by the market makers & i stand by ! so clinical updates or to say "News" as the updates was silence due to the tech transfer you witness the fluctuation's in the share price !

snippet from my research !

At this juncture, the immediate procedural focus is dose escalation. Moving from half-dose to full-dose cohorts is a standard but critical step in early-phase trials, requiring close monitoring for toxicity, particularly cytokine release syndrome and neurotoxicity, which are commonly associated with CAR-T therapies. Each new patient infused at full dose will generate higher-value data on both efficacy and safety, accelerating the determination of an optimal therapeutic window. Parallel to this, the planned inclusion of paediatric patients introduces additional regulatory and clinical considerations. These younger participants will begin at half dose, reflecting a cautious, ethically grounded approach that mirrors the adult trial design but demands tailored oversight in dosing tolerance and immune response🐭.

The gamblers will be using the revolving door of dilution exit before you spin the next buck chasing "What could of been 🐭

Like painting the floor remember where the door is a similar comparison when the share price hits the floor use the fire door🐭

Should Hemogenyx HG-CT-1 efficacy Data in multiple patients then hemo becomes primed for a collaboration/ acquisition target ! the current shares in issue is currently riding @ 6.42m shares giving a buy out valuation £3-6b EPS £465-£930 will not be out of reach but those figures will dehydrate as hemo are cashed strapped & dilution will weaken the EPS on the assumption of placings & a total shares in issue (13m) £230....£450ps this aligns with pumkins valuation:-))

MRD‑negative complete remissions with durability is the metric, should hemogenyx delivers then the timeline accelerates & the valuation explodes !

spins the abacus clean efficacy data...Phase 1 complete: £150m–£240m....Phase 2 start: £300m–£600m...Phase 3 start: £1bn–£2bn...Approval: £3bn–£6bn

the above Aligns with other successful clinical trials/collaborations/acquisitions but the jewel in the crown is Aml Vad will fill in the blank cheque

Can Hg-ct-1 Deliver A Durable MRD-Negative Complete Remissions @ a higher Dose the valuation resets/ f it doesn’t, the upside collapses its as simple as that🐭

The critical Control Point:

Mrd what is it and why it matter MRD = Minimal Residual Disease/referring to the tiny number of cancer cells left in the body after treatment that cannot be seen under a microscope but can be detected with sensitive cytometry flow tests

if Hg-Ct-1 shows 60% MRD-Negative-Cr with durability: ie 10 patients treated with consistent complete remission pattern (not one off) Mrd-negative confirmation Aligning with No sever safety issues, it's a multibagger if not it becomes a Aml car-t trial that "looked good in the early phase but did not change survival

Hemogenyx is not competing on whether it “works”—most AML CAR-T therapies produce responses.

It is competing on whether it can Produce Durable MRD-Negative-Remissions which is where nearly all other c/trials fail🐭

The plums are ripe for picking enjoy the Jam🐭

“Ah yes, the classic ‘I bought lower so it must work’ Fair play on the entry, but the price paid doesn’t validate the science, You’re defending an outcome that hasn’t happened yet but living in hope that is not investing in my book that is Gambling the conclusion to your bet which is a country mile away and that will depend on consistent clean efficacy Data todays Rns was just noise nothing else🐭

Yes great interview open formative interesting honest, thanks for the link you know who you are🐭

Good afternoon Condom:to shift your blockage a dose of truth:When confirmation of dose escalation to the next level "Trending" the market will remain in a "prove it Mode !.....Take care — and when the next catalyst drops, whether it’s dose escalation, patient #4, or pediatric enrolment, I’ll be right here to break it down with you in a Diplomatic vibe,🐭

They filed their annual IND report with the FDA.It confirms the trial is still active and compliant — nothing more. This is mandatory paperwork, not a new milestone: but No mention of the patient moving to the next dose.If they had escalated, they would normally highlight it loudly Hemogenyx declined to do so & a reason for a negative response from the market when the Data is doing the Talking in a positive manner then the market will return Respect thou that may take a further amount of time due to new cohorts enrolled escalates a daisy chain of paper work,

What the Rns does not tell the market/investors: No confirmation that dose escalation has begun.....No update on the fourth patient..No update on paediatric enrolment, despite prior clearance.....No timelines, no milestones, no forward guidance. the RNS only gave what was already known & why the market reacted negatively🐭

The Transfer to Made tech alleviated hemogenyx cash burn, the unanswered questions that the Rns declined to submit to the market, patients that have received the half/optimum dose will now proceed to the full dose "will the next cohorts to enrol eclipse the start of the trial by receiving a half dose/optimum dose or escalate to the full dose ? now moving forward if " Full Dose " the daisy chain of paper work begins hemogenyx simply can not advance but only implying further delays, no doubt this will trigger speculation of passing the Batton to Hype....The cash burn is smouldering with placings in the mist....Sizzle....Sizzle🐭

The market expected confirmation of dose escalation — the RNS didn’t deliver it, and that’s why the price dropped.🐭

Your Thesis is weak " Cheap....Considering....Possibility" confirms you require assistance of Wd-40 to relieve your Piles of verbal tripe🐭